Zorifer poised to fill critical gap for advanced NSCLC with CNS metastases in China, says analyst

China’s National Medical Products Administration (NMPA) has recently approved Zorifer (zorifertinib), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) specifically for the treatment of non-small cell lung cancer (NSCLC) with CNS metastases.

Developed by China’s Alpha Biopharma in collaboration with UK pharma major AstraZeneca (LSE: AZN), this new treatment option is expected to benefit EGFR-mutated NSCLC patients with different levels of CNS metastases, says pharma analytics company GlobalData.

Zorifer Phase III trial demonstrated consistent benefits in patients with intracranial symptoms, EGFR L858R mutations, and multiple lesions, potentially prolonging overall survival with the sequential use of zorifertinib and third-generation EGFR-TKIs.